Signing Agreement with Hong Kong ITF for Re-industrialisation Funding Scheme
17 Sep 2021 (16:32)
Today, Taron Solutions have signed an agreement with the Innovation and Technology Fund (ITF) from HK government and receive funding support to build a smart production line. This state of the art production line will enable Taron to produce biological materials sufficient for various application; ranged from preclinical study, process development ready for commercial manufacturing.
The production line will follow in-house procedure and governess according to GMP guidelines in order to ensure the production process are both reproducible and comply to GMP standard.
Thanks to Taron existing proprietary vector platforms for both microbial and mammalian expression system and culture media technology, this setup will further enhance Taron existing capability and provide our client with services that can push drug candidate to IND filing in a shorter project time.
Today, Taron Solutions have signed an agreement with the Innovation and Technology Fund (ITF) from HK government and receive funding support to build a smart production line. This state of the art production line will enable Taron to produce biological materials sufficient for various application; ranged from preclinical study, process development ready for commercial manufacturing.
The production line will follow in-house procedure and governess according to GMP guidelines in order to ensure the production process are both reproducible and comply to GMP standard.
Thanks to Taron existing proprietary vector platforms for both microbial and mammalian expression system and culture media technology, this setup will further enhance Taron existing capability and provide our client with services that can push drug candidate to IND filing in a shorter project time.
【初創營商】科企初創搶攻市場缺口 團隊國際化助擴外地
|
生物科技初創 2年建5開發渠道
除了金融科技初創外，在新冠肺炎疫情爆發後，大眾逐漸增加對「健康」關注，本地生物科技行業的初創也開始起飛。 其中負責生物藥物委託開發暨製造的初創泰宏科學，其行政總裁兼創始人張安雷指出，如果想創業，可先思考哪些行業或缺口需要填補，他笑指：「當日創立泰宏科學前，就是看到市場上，藥物開發研究和商業之間出現差距。因此，決定藉此尋找商機，填補市場的空缺，幫助企業開發具有商業潛力的藥物。」 據了解，短短兩年間，泰宏科學已建立5個開發渠道及研發4種新藥物，其中一種研發中的藥物是由港府撥款資助，並與一間香港上市製藥公司簽訂諒解備忘錄。 |
Bringing Biologic Drugs to Market | InvestHK
|
For a drug to be successful, it must undergo vigorous procedures to ensure its efficacy and safety prior to its commercial launch. One that may seem promising during the discovery phase may not perform well in clinical trials if it fails in any part of chemistry, manufacturing and control (CMC) requirements.
Source: https://www.investhk.gov.hk/en/case-studies/bringing-biologic-drugs-market.html |
Taron Solutions is One of The Top 10 Finalist at ATEC’s Startup Competition
Taron Solutions Limited is one of 10 finalist start-up companies chosen from over 80+ international start-ups that participated in Asia Technology Entrepreneurship Conference (ATEC) Startup Competition as a finalist on 09 Nov 19. ATEC is a conference hosted jointly by Harvard, Columbia, Stanford and MIT’s business school and there were many investors present at the competition. The company was the only biotechnology company that was chosen to participate as a finalist, which is a win for not only Taron Solutions, but for the sector in Hong Kong.
CEO of Taron Solutions Alan Chang pitching to the judges at ATEC
For Facebook
-ATEC: https://www.facebook.com/ATECstartup/
-photography by Karen Ma: https://www.facebook.com/owrstudio/
For Instagram
-ATEC: @atecstartup
-photography by Karen Ma: @owr_studio
-ATEC: https://www.facebook.com/ATECstartup/
-photography by Karen Ma: https://www.facebook.com/owrstudio/
For Instagram
-ATEC: @atecstartup
-photography by Karen Ma: @owr_studio
Taron Solutions 4000 sqft Headquarter and Laboratory for Drug Product Development
Taron Solutions recently completed the headquarter office as well as a state-of-the-art laboratory to facilitate the company’s work on several first-in-class drug and biosimilar drug projects. The laboratory contains different equipment for analytical testing, tissue culture, DNA/Protein detection, and cell detection, process development, and cell banking. Taron plans on establishing ISO9001 standard by 2020.
The company’s process development lab will contain bioreactors as well as downstream purification for scale-up optimization.
The company’s process development lab will contain bioreactors as well as downstream purification for scale-up optimization.
|
|
Admittance to Hong Kong Science Park Incubio Program
|
Taron Solutions was successfully admitted into Science Park Incubio program right before Chinese New Year and our move in date for the government subsidized laboratory space is on April 15th.
Taron Solutions are able to carry on some of our advanced R&D and early development service work at this space. Admission in the four year Incubio program include a government grant of HKD 6M paid over the duration of the program. This money can be used towards our Science Park rent and for hiring PhDs. |
Our pilot facility handles early stage bioprocess development up to Phase 2 GMP clinical production
Pilot Facility (Under Construction)
- Size of facility: Approximately 14,000 sq. ft
- Production Scale: Up to 500 L (x 2) with potential to expand
- Our facility handles cell banking, early stage bioprocess development, up to Phase 2 GMP clinical production
- In-house supporting functions such as QC testing labs, GMP warehouse, bio-waste and waste water treatment, utilities (e.g., HVAC, WFI, Clean Steam etc.), process automation systems
- Commencement for GMP manufacturing is ~2 years from the start of facility renovation